Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors.
Gerald Steven Falchook
Consultant or Advisory Role - EMD Serono
Honoraria - EMD Serono
Research Funding - EMD Serono
Other Remuneration - EMD Serono
David S. Hong
No relevant relationships to disclose
Hesham M. Amin
Research Funding - EMD Serono
Siqing Fu
No relevant relationships to disclose
Sarina Anne Piha-Paul
No relevant relationships to disclose
Filip Janku
No relevant relationships to disclose
J. Gabrielle Granda
No relevant relationships to disclose
Hongxia Zheng
Employment or Leadership Position - EMD Serono
Manfred B. Klevesath
Employment or Leadership Position - Merck KGaA
Karola Köhler
Consultant or Advisory Role - Merck KGaA
Friedhelm Bladt
Employment or Leadership Position - Merck KGaA
Andreas Johne
Employment or Leadership Position - Merck KGaA
Razelle Kurzrock
Research Funding - Merck Serono